Certified by Founder Lodge
Delfi Diagnostics
United States - Baltimore, Maryland
START UP
1 Disclosed Funding Rounds $225,000,000
0 Participating Investments
-
Founded date
2019
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| July, 18 ,2022 | Series B | $225,000,000 |
Menlo Ventures
Point72 Ventures
OrbiMed
Foresite Capital
Osage University Partners (OUP)
DFJ Growth
Northpond Ventures
Point Field Partners
INITIATE
Open Field Capital LLC
PTX Capital
Samsara Capital
AV8 Ventures
Illumina Ventures
Windham Venture Partners
IDRx
CAMP4 Therapeutics
xilis
Manifold Bio
OTPLESS | $3,500,000 | (May 17, 2024)
Watershed Health | $13,600,000 | (May 17, 2024)
Aeropay | $20,000,000 | (May 17, 2024)
c/side | $1,700,000 | (May 17, 2024)
SINE Digital | $2,500,000 | (May 17, 2024)
